2015 American Transplant Congress
Ligation of the Native Ureter for Treatment of Urinary Fistula in Kidney Transplantation: Is It Safe?
Division of Urology, Renal Transplantation Unit, University of Sao Paulo, Sao Paulo, Brazil.
Purpose: Urinary fistula and ureteral stenosis occur respectively in 2-5% and 2-7.5% after kidney transplantation. Within the different causes of stenosis and fistula after kidney…2015 American Transplant Congress
Alterations in Peripheral Blood B Cell Subpopulations in Kidney Transplant Recipients With DSA
Peripheral blood B cell subpopulations were assessed over time (1, 3, 6, 9, and 12 months) in living donor kidney transplant recipients undergoing thymoglobulin (n…2015 American Transplant Congress
Comprehensive Study of 3 Nomenclatures to Discriminate CD8 Subsets in Healthy Volunteers and in Kidney Transplant Recipients
Objective. Historical classification to distinguish central memory (CM), naïve, effector memory (EM), and terminally-differentiated effector memory (TEMRA) CD8 T cells is based on CD45RA and…2015 American Transplant Congress
Divergence in Risk Factors for Graft Loss and Death Across Race May Mediate Kidney Transplant Outcome Disparity
Differences in outcomes between African American and non-African American kidney transplant recipients may reflect disparate access to health care. Minimizing this disparity demands a deeper…2015 American Transplant Congress
Non-Invasive Immune Monitoring Assay in Transplant Recipients
A reliable non-invasive assay of immune responsiveness would help to predict the development of chronic rejection, stable function or tolerance in transplant recipients. Our aim…2015 American Transplant Congress
Treatment With Everolimus and Reduced-Exposure Cyclosporine Is Efficacious in De Novo Renal Transplant Recipients at Increased Risk for Efficacy Failure: Post-Hoc Analysis from the A2309 Study
1For the A2309 Study Group, Italy; 2Novartis, Basel, Switzerland.
Purpose: Data is limited on the effect of everolimus (EVR) based regimens in renal transplant recipients (RTxR) who are at increased risk for rejection and…2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…2015 American Transplant Congress
Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation
Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
PurposeTacrolimus is one of the most frequently used immunosuppressants in pediatric kidney transplantation (KT) as in adult. In Pediatric kidney recipients, it is more important…2015 American Transplant Congress
Program-Effect Attenuation With Time Posttransplant
The program-specific reports produced by SRTR include 1-month, 1-year, and 3-year posttransplant graft and patient survival measures. The 1-month and 1-year measures use the same…2015 American Transplant Congress
Clinical Subclassifiation of ABMR Phenotypes: Recognizing Variation in Presentation
Alberta Transplant Applied Genomics Centre, Edmonton, Canada.
The diagnosis of ABMR in kidney transplants is based on ptc-, g- and cg-lesions in biopsies and donor-specific antibody (DSA). To recognize the actual phenotypes…
- « Previous Page
- 1
- …
- 510
- 511
- 512
- 513
- 514
- …
- 531
- Next Page »